# A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

> **NCT01662869** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 564 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** 5-Fluoruracil
- **DRUG:** Folinic acid
- **DRUG:** Onartuzumab
- **DRUG:** Oxaliplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01662869
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 564 (ACTUAL)
- **Last updated:** 2016-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01662869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01662869, "A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01662869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*